Dataset Information

Unraveling the immunological roles of murine serum amyloid A3 in aortic immune cell subsets during atherosclerosis progression

ABSTRACT: Atherosclerosis is a growing concern in developed nations, necessitating the identification of therapeutic targets for advancing personalized medicine. Serum amyloid A3 (Saa3) has been linked to accelerated plaque progression by affecting cholesterol metabolism and modulation of inflammation. We hypothesize that knocking out Saa3 (Saa3-/-) could mitigate plaque development by regulating aortic immune cell subsetscompositions during atherosclerosis progression. Using a murine model, we induced atherosclerosis via a gain-of-function mutant PCSK9-encoding adeno-associated viral vector (AAVmPCSK9) in wild-type (WT) and Saa3-/- mice. Single-cell RNA sequencing revealed that Saa3-/- mice developed smaller plaques than WT mice, with and single-cell RNA sequencing revealed significant differences in aortic immune cell populations, particularly among aortic macrophages. Saa3-/-Trem2hi macrophages, characterized by high Gpnmb, Lpl, and Spp1 expressions, predominated over the typical resident foamy macrophages in WT mice.Saa3-/- compared to WT mice. SAA3 regulates cholesterol metabolism and inflammatory responses in foamy macrophages. Notably, aortic immune cells in atherosclerotic Saa3-/- mice also showed enhanced intercellular immune communication and increased signaling interactions, suggesting a shift towards an anti-inflammatory and tissue-repairing phenotype. Our study highlights the potential of Saa3 as a therapeutic target forkey modulator of aortic immune cells that impact atherosclerosis progression.

ORGANISM(S): Mus musculus

PROVIDER: GSE270922 | GEO | 2025/06/27

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Senescent foamy macrophages are the key pathogenic drivers of atherosclerosis (AS) progression and plaque stability. The RNA N6-methyladenosine (m6A) modification plays an important role in the development of various diseases. However, its role in foamy macrophage aging during AS is still not clarified. To assess m6A methylation levels and m6A modifying enzyme profiles, the infiltrated macrophages were sorted using CD68+ magnetic beads from plaque tissues of patients with AS and high-fat diet feeding Apoe-/- mice. The ALKBH5f/f, Lyz2Cre, Apoe-/- mice were constructed to observe senescent macrophage infiltrated in plaques and AS progression. The RNA-seq, MeRIP, RIP and dual luciferase assays were performed to explore the mechanisms of ALKBH5-mediated formation of senescent macrophage. Downregulated m6A methylation levels and upregulated ALKBH5 expression were observed in aortic plaques and infiltrated macrophages from AS patients and mice. Compared with control mice, ALKBH5f/f, Lyz2Cre, Apoe-/- mice decreased AS plaques and enhanced plaque stability by suppressing senescence of foamy macrophages and senescence-associated secretory phenotypes. In addition, the data of the RNA-seq, MeRIP, RIP and dual luciferase assays showed that ALKBH5 deletion reduced the mRNA level of CC chemokine ligand 5 (CCL5) by increased m6A methylation in macrophages. Actinomycin D assay indicated ALBH5 knockout destroyed stability of Ccl5 mRNA. Mechanismly, ALKBH5 promotes senescent macrophage formation by CCL5/CC chemokine receptor 5 (CCR5)/mTORC1/autophagy signaling. And ALKBH5 induced macrophage derived CCL5 recruits increasingly CD8+IFNγ+ T cells by CCL5-CCR5 axis. Furthermore, the application of ALKBH5 inhibitor IOX-1 and CCR5 monoclonal antibody Adaptavir are potential clinical interventions for the inhibition of senescent macrophage formation and AS progress. Myeloid ALKBH5 deletion mitigates AS progression by suppressing the formation of senescent macrophages and the recruitment of CD8+IFNγ+ T cells. These findings favour the ALKBH5/CCL5/CCR5 signaling as novel targets for atherosclerosis therapy.

Project description:Purpose: The goals of this study is to evaluate the impact of LXRa phosphorylation at S196 in immune cells on atherosclerosi and obesity, on gene expression via RNA-seq. Lab Methods: Bone marrow from LXRa WT and S196A mice was transplanted into Ldlr-/- mice, which were fed a high fat, high cholesterol diet for 16 weeks prior to evaluation of atherosclerosis and obesity. Plaque CD68+ and T cells, and pWAT macrophages and T cells mRNA profiles of LXRa WT and S196A mice were generated by RNA-seq using Illumina HiSeq 2500 (plaque CD68+ samples) or HiSeq 4000 (Plaque T cells and pWAT FBC, FB and T cells samples). Bioinformatics Methods: Quality control and Illumina adapter removal was performed on the raw sequencing output, followed by mapping of each read pair to the GRCm38.96 transcriptome in order to generate the mRNA profile of each sample. Sample groups from different tissues as well as groups from wild-type or mutant samples were compared against each other for differential gene expression. Results: we analyzed genes differentially expressed in plaque LXRa S196A and found that LXRa S196A induced 365 and repressed 205 genes in CD68+ (LogFC > 0.6, p-value < 0.05), and induced 1,578 genes and repressed 2,392 genes in plaque T cells compared to LXRa WT (LogFC > 1, FDR < 0.05). In pWAT, LXRa S196A vs WT analysis showed that LXRa S196A repressed 419 genes and induced 379 genes in FBC, induced 182 genes and repressed 228 genes in FB, and 624 genes were induced and 622 genes were repressed in LXRa WT (LogFC > 1, FDR < 0.05). Conclusions: This study is the first detailed analysis of plaque and pWAT immune cells transcriptomes from LXRa S196A in bone marrow cells of LDLR-/- mice under high fat and high cholesterol diet, generated by RNA-seq. We demonstrated that LXRa S196A is largely affecting transcriptome of immune cells in atherosclerotic plaque and pWAT. The transcriptome remodeling observed is tissue and cell specific, and controls atherosclerosis and obesity progression.

Project description:Background: Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP), particularly in DNMT3A, TET2, and JAK2, are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. However, whether CHIP is associated with increased risk of peripheral artery disease (PAD) remains unknown. In addition, chemotherapy frequently causes mutations in DNA Damage Repair (DDR) genes TP53 and PPM1D, and whether CHIP caused by somatic mutations in DDR genes results in increased risk of atherosclerosis is unclear. We sought to test whether CHIP, and CHIP caused by DDR genes, associates with incident peripheral artery disease (PAD) and atherosclerosis. Methods: We identified CHIP among 50,122 exome sequences in individuals from UK and Mass General Brigham Biobanks and tested CHIP status (N=2,851) with incident PAD and atherosclerosis across multiple arterial beds. To mimic the human scenario of clonal hematopoiesis and test whether the expansion of p53-deficient hematopoietic cells contributes to atherosclerosis, a competitive bone marrow transplantation (BMT) strategy was used to generate atherosclerosis-prone Ldlr-/- chimeric mice carrying 20% Trp53-/- hematopoietic cells (20% KO-BMT mice). We then evaluated aortic plaque burden and plaque macrophage accumulation 12 weeks after grafting. Results: CHIP associated with incident PAD (HR 1.7; P=2.2x10-5) and atherosclerosis in multiple beds (HR 1.3; P=9.7x10-5), with increased risk among individuals with DDR CHIP (HR 2.0; P=0.0084). Among atherosclerosis-prone Ldlr null mice, the p53 -/- 20% KO-BMT mice demonstrated increased aortic plaque size (p=0.013) and accumulation of p53-/- plaque macrophages (P<0.001), driven by an abundance of p53-deficient plaque macrophages. The expansion of p53-deficient cells did not affect the expression of the pro-inflammatory cytokines IL-6 and IL-1β in the atherosclerotic aortic wall. Conclusions: Our findings highlight the role of CHIP as a broad driver of atherosclerosis across the entire arterial system, with evidence of increased plaque among p53 -/- 20% KO-BMT mice via expansion of plaque macrophages. These observations provide new insight into the link between CHIP and cardiovascular disease, and lend human genetic support to the concept that post-cytotoxic chemotherapy patients may benefit from surveillance for atherosclerotic conditions in addition to therapy-related myeloid neoplasms.

Dataset Information

Unraveling the immunological roles of murine serum amyloid A3 in aortic immune cell subsets during atherosclerosis progression

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets